ALEC
Alector, Inc.·Healthcare
2.45
2.083%(+0.05)
Market ClosedLast Updated: — ET
52W L: $0.9052W H: $3.40
ALEC NEWS
zacks.com
Mar 10
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
247wallst.com
Mar 10
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each.
seekingalpha.com
Mar 6
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
zacks.com
Feb 25
Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.02 per share a year ago.
globenewswire.com
Feb 25
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's Disease), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's Disease) and AL064 (ABC-enabled Tau siRNA for Alzheimer's Disease) Independent interim futility analysis of the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer's disease expected in the first half of 2026 $256.0 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported fourth quarter and full year 2025 financial results and recent portfolio and business updates.
globenewswire.com
Feb 24
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a corporate presentation at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 pm ET.
